Cargando…

Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer

SIMPLE SUMMARY: Molecular signatures predictive of recurrence-free survival (RFS) and castration resistance are critical for treatment decision-making in prostate cancer (PCa), but the robustness of current signatures is limited. This study aims to identify castration-resistant PCa (CRPC)-associated...

Descripción completa

Detalles Bibliográficos
Autores principales:	A, Jun, Zhang, Baotong, Zhang, Zhiqian, Hu, Hailiang, Dong, Jin-Tang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927111/ https://www.ncbi.nlm.nih.gov/pubmed/33671634 http://dx.doi.org/10.3390/cancers13040917

Ejemplares similares

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
por: Hakozaki, Yuji, et al.
Publicado: (2022)

Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients
por: Pölsterl, Sebastian, et al.
Publicado: (2017)

Recurrence‐associated gene signature optimizes recurrence‐free survival prediction of colorectal cancer
por: Tian, Xianglong, et al.
Publicado: (2017)

Novel Multiple miRNA-Based Signatures for Predicting Overall Survival and Recurrence-Free Survival of Colorectal Cancer Patients
por: Qian, Jinrong, et al.
Publicado: (2019)

Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer
por: Long, Gongwei, et al.
Publicado: (2021)

Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer
por: Yang, Cheng, et al.
Publicado: (2022)

Predicting survival time for metastatic castration resistant prostate cancer: An iterative imputation approach
por: Deng, Detian, et al.
Publicado: (2016)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

A predictive model of overall survival in patients with metastatic castration-resistant prostate cancer
por: Mahmoudian, Mehrad, et al.
Publicado: (2019)

Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer
por: Pang, Xiaocong, et al.
Publicado: (2019)

A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy
por: Shi, Run, et al.
Publicado: (2019)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

Gene signatures predict biochemical recurrence‐free survival in primary prostate cancer patients after radical therapy
por: Su, Qiang, et al.
Publicado: (2021)

A Glycolysis-Related Five-Gene Signature Predicts Biochemical Recurrence-Free Survival in Patients With Prostate Adenocarcinoma
por: Xu, Zijun, et al.
Publicado: (2021)

A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer
por: Ke, Zhi-Bin, et al.
Publicado: (2022)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Novel agents in the management of castration resistant prostate cancer
por: Chaturvedi, Shruti, et al.
Publicado: (2014)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
por: Leung, David Ka-Wai, et al.
Publicado: (2021)

A gene expression signature predicts recurrence-free survival in meningioma
por: Olar, Adriana, et al.
Publicado: (2018)

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients
por: Hendriks, Rianne J., et al.
Publicado: (2018)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer
por: Briones, Juan, et al.
Publicado: (2021)

Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease
por: Wang, Bo-Ren, et al.
Publicado: (2022)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration
por: Long, Xingbo, et al.
Publicado: (2020)

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort
por: Rouyer, Magali, et al.
Publicado: (2019)

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
por: Hamano, Itsuto, et al.
Publicado: (2020)

Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
por: Shiga, Motoki
Publicado: (2016)

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer()
por: Heidegger, Isabel, et al.
Publicado: (2013)

Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma
por: Gu, Jing-Xian, et al.
Publicado: (2019)

KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1α accumulation
por: Ci, Xinpei, et al.
Publicado: (2015)

Establishment of a five‐enzalutamide‐resistance‐related‐gene‐based classifier for recurrence‐free survival predicting of prostate cancer
por: Chen, Jing, et al.
Publicado: (2022)

AB122. MicroRNA-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence
por: Xu, Chuanliang, et al.
Publicado: (2014)

Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer
por: Pak, Sahyun, et al.
Publicado: (2020)

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
por: Rasmussen, Kelli M., et al.
Publicado: (2023)

Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients
por: Zhang, Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f0ugghtp6urdft141hhgess6sp